Abstract
Corynebacterium pyruviciproducens (C. pyruviciproducens, CP), as a newly discovered immunomodulator, has been confirmed to have a stronger immunoregulation than Propionibacterium acnes (P. acnes) of the traditional immune adjuvant, by previous experiments with model antigen ovalbumin and sheep red blood cells. Here, it was designed to assess its ability to resist methicillin-resistant Staphylococcus aureus (MRSA), since MRSA as a vital gram positive pathogen is characterized by high morbidity and mortality. In this report, it was indicated that C. pyruviciproducens and its peptidoglycan (CP-PGN) could help to be against bloodstream infection of MRSA with raised survival rate, decreased bacteria load and alleviated systemic inflammation, and these effects of CP-PGN were more pronounced. However, the whole CP was inclined to prevent localized abdominal infection of MRSA from progressing to a systemic infection. And they showed the potential as a therapeutic drug alone or combined with vancomycin. The diversity of capacity of activating macrophages induced by CP and CP-PGN may result in distinct resistance to MRSA in different infection models. Furthermore, both CP and CP-PGN induced M1 macrophages. In conclusion, CP and its PGN could act as promising immune agents to treat and prevent MRSA infection.
Highlights
C. pyruviciproducens is a newly discovered bacterial immunoregulation without known pathogenic components
CP and C. pyruviciproducens and its peptidoglycan (CP-PGN) could protect mice against methicillinresistant Staphylococcus aureus (MRSA) as potential preventive and therapeutic drugs but with different advantages in various infection models, that may be due to diversity of capacity of activating macrophages induced by CP and CP-PGN, both of them induced M1 macrophages
The results suggested that CP-PGN possessed the characteristics of peptidoglycan
Summary
C. pyruviciproducens is a newly discovered bacterial immunoregulation without known pathogenic components. Repeated vancomycin treatment can increase the risk of developing resistance to critical antibiotic. These challenges necessiate the research for novel therapeutic approaches for MRSA infection. Macrophages occupy a unique niche in the immune system They are effector cells that contribute to fight infection and inflammation[11]. Two treatment models with CP alone or combined with vancomycin were designed to determine its therapeutic effect for MRSA infection. CP and CP-PGN could protect mice against MRSA as potential preventive and therapeutic drugs but with different advantages in various infection models, that may be due to diversity of capacity of activating macrophages induced by CP and CP-PGN, both of them induced M1 macrophages
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
